The Quantellect read.As of Nov 19, 2026, 4 active firms cover Beauty Health Co: 1 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $0.90 to $11.00 (about 12.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $3.73 sits 70% below the current $12.27. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.75 next quarter toward $4.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Neutral
Strong Buy00%
Buy125%
Neutral375%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$3.73
-69.6% downside
Average target across 4 active firms as of Nov 19, 2026 vs $12.27 current
Highest Target$11.00
Average Target$3.73
Lowest Target$0.90
Detailed analyst forecasts for SKIN
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 1 of 4 active firms rate SKIN a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SKIN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.75
Range $-0.99 – $-0.52 · 4 analysts · -25% YoY
Next period, 4 analysts expect Beauty Health Co to earn $-0.75 a share (range $-0.99 – $-0.52), versus $-1.00 a year earlier. Full-year consensus is $3.05, growing to $4.48 the year after.
REVENUE · NEXT QUARTER
$65.1M
Range $62.9M – $68.1M · 4 analysts · +0% YoY
Revenue is expected to reach $65.1M (range $62.9M – $68.1M), +0.3% year-over-year. Full-year consensus is $285.2M, rising to $288.9M next year.
Top analysts covering Beauty Health Co
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SKIN.
#1
George Kelly
Roth MKM · Rank #292
Buy
$40.00+226.1% to target
Overall win rate
44%
+ Follow
#2
Jonathan Block
Stifel · Rank #294
Neutral
$2.00-83.7% to target
Overall win rate
36%
+ Follow
#3
Bruce Jackson
Benchmark · Rank #487
Neutral
No targeton SKIN
Overall win rate
36%
+ Follow
#4
Susan Anderson
Canaccord Genuity · Rank #520
Neutral
$1.00-91.8% to target
Overall win rate
31%
+ Follow
#5
SW
Sydney Wagner
Jefferies
Neutral
$11.00-10.3% to target
Coverage
—
+ Follow
SKIN stock forecast FAQ
What is SKIN's average 12-month price target?+
The 4 active firms with a live target average $3.73 for Beauty Health Co over the next 12 months, ranging from a $11.00 high to a $0.90 low, as of Nov 19, 2026.
Is SKIN stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 4 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SKIN?+
The Street-high target is $11.00 (Jefferies), and the Street-low is $0.90 (TD Cowen). The average of all 4 active-firm targets is $3.73.
How many active Wall Street firms cover SKIN?+
4 active firms have a recognized rating on Beauty Health Co as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SKIN?+
Among analysts who currently cover SKIN, George Kelly of Roth MKM has the strongest overall Quantellect track record (Rank #292). Their current call is Buy with a $40.00 target.
What is Beauty Health Co's projected EPS for next quarter?+
The consensus estimate is $-0.75 per share (range $-0.99 – $-0.52) across 4 analysts. Full-year EPS is projected at $3.05, rising to $4.48 the following year.
How much revenue is Beauty Health Co expected to report next quarter?+
Consensus revenue is $65.1M (range $62.9M – $68.1M). Full-year revenue is projected at $285.2M, growing to $288.9M next year.
Have analysts been upgrading or downgrading SKIN lately?+
As of Nov 19, 2026, 1 of 4 active firms rate SKIN a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SKIN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.